ERBB2 and breast carcinoma: The results showed that higher NFIB expression was correlated with a worse distant metastasis-free survival (DMFS) as well as with relapse-free survival (RFS) of breast cancer patients of HER2+ subtypes, but not of other subtypes (Fig. 8e and Supplementary Fig. 6a).